Abstract 195: SPARCL1 is an angiocrine inhibitor of tumorigenesis in colorectal carcinoma
Authors: Clara Tenkerian, Daniela Regensburger, Victoria Langer, Anika Klingler, Anne Borau, Heinrich Sticht, Andreas Ramming, Thomas Wohlfahrt, Benjamin Schmid, Valérie Méniel, Robert Grützmann, Nathalie Britzen-Laurent, Vera Schellerer, Michael Stürzl, Elisabeth Naschberger
Journal: Cancer Research (2019)

Abstract Colorectal carcinoma (CRC) is the second leading cause of cancer-related mortality worldwide. The contribution of the tumor microenvironment (TME) to CRC pathogenesis is well established, whereby the dominance of one immune response (Th1) over another (Th17) can yield opposite effects on patient prognosis. We recently reported on TME-dependent vascular plasticity in CRC and identified the secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) as a marker thereof. SPARCL1 is a matricellular protein expressed and secreted exclusively by the vascular system (endothelial and mural cells). In previous studies, gene expression analyses in CRC tumor tissues of different patient cohorts congruently showed a significant loss of SPARCL1 in colon and rectum adenocarcinomas as compared to uninvolved colon tissues and indicated that this loss is TME-dependent. Specifically, high SPARCL1 expression was associated with a Th1-TME, reduced incidence of distant metastasis and increased cancer-related survival. In contrast, SPARCL1 expression was lost in aggressive CRC with a non-Th1-TME. Here we show in functional analyses that SPARCL1 inhibits angiogenesis in different in vitro (endothelial cell proliferation, capillary formation on matrigel, 3D spheroid sprouting), ex vivo (fetal mouse metatarsal explant) and in vivo (FITC-dextran vascular permeability) assays. Moreover, increased tumor cell colonization is detected in the lungs of SPARCL1-knockout mice, further consolidating the anti-tumorigenic function of SPARCL1. To characterize the molecular mechanism of SPARCL1 anti-angiogenic function, we identified the TGF-β co-receptor Endoglin as a cellular receptor for SPARCL1 and found that SPARCL1 regulates ERK1/2 activity. The RAS-ERK pathway is amplified in more than half of all CRC tumors and as such is considered an important therapeutic target. Interestingly, SPARCL1 regulates ERK1/2 not only through phosphorylation but also through its subcellular localization. We show that SPARCL1 induces ERK1/2 phosphorylation preferentially in the cytoplasm and activates specifically cytoplasmic substrates downstream of it. Finally, we show that the regulation of ERK1/2 by SPARCL1 is not limited to endothelial cells but extends to epithelial CRC cells, indicative of autocrine and paracrine functions of SPARCL1. In summary, our study indicates that SPARCL1 is a TME-dependent angiocrine tumor suppressor in CRC acting through the regulation of ERK1/2 activity. This finding opens novel perspectives elucidating the crosstalk between the TME and the ERK signaling pathway and accordingly may enable new strategies to overcoming drug resistance and/or therapy-oriented patient stratification. Citation Format: Clara Tenkerian, Daniela Regensburger, Victoria Langer, Anika Klingler, Anne Borau, Heinrich Sticht, Andreas Ramming, Thomas Wohlfahrt, Benjamin Schmid, Valérie Méniel, Robert Grützmann, Nathalie Britzen-Laurent, Vera Schellerer, Michael Stürzl, Elisabeth Naschberger. SPARCL1 is an angiocrine inhibitor of tumorigenesis in colorectal carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 195.